MétaCan
Menu
Back to cohort
Record W2584983278 · doi:10.1038/emm.2016.143

Therapeutic effect of the immunomodulatory drug lenalidomide, but not pomalidomide, in experimental models of rheumatoid arthritis and inflammatory bowel disease

2017· article· en· W2584983278 on OpenAlexafffundabout
Belén López‐Millán, Rafael Díaz de la Guardia, Heleia Roca-Ho, Carmen M. García‐Herrero, Jessie R. Lavoie, Michael Rosu‐Myles, Elena González‐Rey, Francisco O’Valle, Gabriel Criado, Mario Delgado, Pablo Menéndez

Bibliographic record

VenueExperimental & Molecular Medicine · 2017
Typearticle
Languageen
FieldMedicine
TopicMultiple Myeloma Research and Treatments
Canadian institutionsHealth Canada
FundersHealth CanadaGeneralitat de Catalunya
KeywordsLenalidomideThalidomidePomalidomideMedicineRheumatoid arthritisInflammatory bowel diseasePharmacologyImmunologyLeflunomideMultiple myelomaInternal medicineDisease

Abstract

fetched live from OpenAlex

Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; however, its inherent high toxicity has led to the development of more powerful and safer thalidomide analogs, including lenalidomide and pomalidomide. These are new generation IMiDs that exhibit direct antitumor activity as well as anti-inflammatory/immunomodulatory properties, and are FDA-approved for the treatment of several hematological malignances. Here we investigated the potential therapeutic effects of lenalidomide and pomalidomide in several experimental murine models of autoimmune/inflammatory diseases: 2,4,6-trinitrobenzene sulfonic acid- and dextran sulfate sodium-induced inflammatory bowel disease and type II collagen-induced arthritis. Lenalidomide displayed a strong therapeutic effect in all these models of autoimmune/inflammatory diseases, while the effect of pomalidomide was less pronounced. In vitro experiments confirmed the immunosuppressive effect of both IMiDs on the proliferative response of stimulated human lymphocytes and on the balance of secreted cytokines toward an anti-inflammatory profile. We conclude that lenalidomide may offer a therapeutic opportunity against autoimmune/inflammatory diseases. Trials in mice find the immunomodulatory drug lenalidomide might help treat rheumatoid arthritis (RA) and inflammatory bowel disease (IBS). Lenalidomide is a chemical analog of thalidomide, the drug notorious for causing devastating birth defects when given to pregnant women in the late 1950s and early 1960s. A new generation of safer analogs, however, is showing useful activity in autoimmune and inflammatory conditions, and cancer. Pablo Menendez and colleagues at the University of Barcelona, with co-workers elsewhere in Spain and in Canada, examined the effect of lenalidomide and the related drug pomalidomide in mouse models of RA, an autoimmune disease, and IBS. Lenalidomide displayed a strong therapeutic effect while that of pomalidomide was less pronounced. Further research to reveal the mechanism of action of these drugs could lead to useful new therapies for human disease.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.302
Teacher spread0.289 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations28
Published2017
Admission routes3
Has abstractyes

Explore more

Same venueExperimental & Molecular MedicineSame topicMultiple Myeloma Research and TreatmentsFrench-language works237,207